Ionic immune suppression within the tumour microenvironment limits T cell effector function

Nature

Volumn 537, Issue 7621, 2016, Pages 539-543

  Eil, Robert ^a,d   Vodnala, Suman K ^a   Clever, David ^a   Klebanoff, Christopher A ^a,b   Sukumar, Madhusudhanan ^a   Pan, Jenny H ^a   Palmer, Douglas C ^a   Gros, Alena ^a,e   Yamamoto, Tori N ^a   Patel, Shashank J ^a   Guittard, Geoffrey C ^a   Yu, Zhiya ^a   Carbonaro, Valentina ^c   Okkenhaug, Klaus ^c   Schrump, David S ^a   Linehan, W Marston ^a   Roychoudhuri, Rahul ^c   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c BABRAHAM INSTITUTE   (United Kingdom)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; POTASSIUM CHANNEL KV1.3; POTASSIUM ION; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MONOVALENT CATION; POTASSIUM; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE;

AMINO ACID; BODY FLUID; CANCER; CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; IMMUNE RESPONSE; POTASSIUM; RODENT; SURVIVAL; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; EFFECTOR CELL; ENZYME PHOSPHORYLATION; EXTRACELLULAR FLUID; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA B16; MEMBRANE POTENTIAL; MOUSE; NONHUMAN; POTASSIUM CELL LEVEL; POTASSIUM TRANSPORT; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METABOLISM; NECROSIS; PATHOLOGY; PROCEDURES; SURVIVAL ANALYSIS; T LYMPHOCYTE; TUMOR ESCAPE;

MUS;

ANIMALS; CATIONS, MONOVALENT; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; KV1.3 POTASSIUM CHANNEL; MALE; MELANOMA; MEMBRANE POTENTIALS; MICE; NECROSIS; POTASSIUM; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TOR SERINE-THREONINE KINASES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84989172165     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature19364     Document Type: Article

References (46)

1. Mellman, I., Coukos, G. and Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011).
2. Richards, C. H., Mohammed, Z., Qayyum, T., Horgan, P. G. and McMillan, D. C. The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. Future Oncol. 7, 1223-1235 (2011).
3. Li, G. et al. EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex. Nat. Commun. 3, 667 (2012).
4. Zhou, P. et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 506, 52-57 (2014).
5. Sitkovsky, M. and Lukashev, D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat. Rev. Immunol. 5, 712-721 (2005).
6. Ho, P. C. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162, 1217-1228 (2015).
7. Zimmerli, W. and Gallin, J. I. Pus potassium. Inflammation 12, 37-43 (1988).
8. Mirrakhimov, A. E., Ali, A. M., Khan, M. and Barbaryan, A. Tumor Lysis Syndrome in solid tumors: an up to date review of the literature. Rare Tumors 6, 68-76 (2014).
9. Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 (2014).
10. Feske, S. ORAI1 and STIM1 deficiency in human and mice: roles of storeoperated Ca2+ entry in the immune system and beyond. Immunol. Rev. 231, 189-209 (2009).
11. Omilusik, K. et al. The Ca(v)1.4 calcium channel is a critical regulator of T cell receptor signaling and naive T cell homeostasis. Immunity 35, 349-360 (2011).
12. Li, F. Y. et al. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature 475, 471-476 (2011).
13. Wu, C. et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 496, 513-517 (2013).
14. Wiig, H., Tenstad, O., Iversen, P. O., Kalluri, R. and Bjerkvig, R. Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair 3, 12 (2010).
15. Haslene-Hox, H. et al. A new method for isolation of interstitial fluid from human solid tumors applied to proteomic analysis of ovarian carcinoma tissue. PLoS One 6, e19217 (2011).
16. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
17. Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924 (2011).
18. Goldman, D. E. Potential, impedance, and rectification in membranes. J. Gen. Physiol. 27, 37-60 (1943).
19. Hodgkin, A. L. and Huxley, A. F. A quantitative description of membrane current and its application to conduction and excitation in nerve. J. Physiol. 117, 500-544 (1952).
20. Buck, M. D., OSullivan, D. and Pearce, E. L. T cell metabolism drives immunity. J. Exp. Med. 212, 1345-1360 (2015).
21. Taffs, R. E., Redegeld, F. A. and Sitkovsky, M. V. Modulation of cytolytic T lymphocyte functions by an inhibitor of serine/threonine phosphatase, okadaic acid. Enhancement of cytolytic T lymphocyte-mediated cytotoxicity. J. Immunol. 147, 722-728 (1991).
22. Liu, Q. H. et al. Modulation of Kv channel expression and function by TCR and costimulatory signals during peripheral CD4+ lymphocyte differentiation. J. Exp. Med. 196, 897-909 (2002).
23. Wulff, H. et al. The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. J. Clin. Invest. 111, 1703-1713 (2003).
24. Cahalan, M. D. and Chandy, K. G. The functional network of ion channels in T lymphocytes. Immunol. Rev. 231, 59-87 (2009).
25. Cidad, P. et al. Kv1.3 channels can modulate cell proliferation during phenotypic switch by an ion-flux independent mechanism. Arterioscler. Thromb. Vasc. Biol. 32, 1299-1307 (2012).
26. Voronkov, M., Braithwaite, S. P. and Stock, J. B. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimers disease. Future Med. Chem. 3, 821-833 (2011).
27. Hla, T. and Dannenberg, A. J. Sphingolipid signaling in metabolic disorders. Cell Metab. 16, 420-434 (2012).
28. Munoz-Planillo, R. et al. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38, 1142-1153 (2013).
29. Wolfs, J. L. et al. Direct inhibition of phospholipid scrambling activity in erythrocytes by potassium ions. Cell. Mol. Life Sci. 66, 314-323 (2009).
30. Reeves, E. P. et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 416, 291-297 (2002).
31. Acquavella, N. et al. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol. Res. 3, 37-47 (2015).
32. Budak, Y. U., Huysal, K. and Polat, M. Use of a blood gas analyzer and a laboratory autoanalyzer in routine practice to measure electrolytes in intensive care unit patients. BMC Anesthesiol. 12, 17 (2012).
33. Wargo, J. A. et al. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol. Immunother. 58, 383-394 (2009).
34. Goff, S. L. et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J. Clin. Oncol. 34, 2389-2397 (2016).
35. Vahedi, G. et al. STATs shape the active enhancer landscape of T cell populations. Cell 151, 981-993 (2012).
36. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511-515 (2010).
37. van der Windt, G. J. et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36, 68-78 (2012).
38. Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387-1390 (2015).
39. Lu, Y. C. et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin. Cancer Res. 20, 3401-3410 (2014).
40. Jimenez-Perez, L. et al. Molecular determinants of Kv1.3 potassium channels-induced proliferation. J. Biol. Chem. 291, 3569-3580 (2016).
41. Turowski, P., Favre, B., Campbell, K. S., Lamb, N. J. and Hemmings, B. A. Modulation of the enzymatic properties of protein phosphatase 2A catalytic subunit by the recombinant 65-kDa regulatory subunit PR65a. Eur. J. Biochem. 248, 200-208 (1997).
42. Xing, Y. et al. Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins. Cell 127, 341-353 (2006).
43. Hand, T. W. et al. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc. Natl Acad. Sci. USA 107, 16601-16606 (2010).
44. Liu, F. and Whitton, J. L. Cutting edge: re-evaluating the in vivo cytokine responses of CD8+ T cells during primary and secondary viral infections. J. Immunol. 174, 5936-5940 (2005).
45. Palmer, D. C. et al. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J. Exp. Med. 212, 2095-2113 (2015).
46. Clark, J. et al. Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. Nat. Methods 8, 267-272 (2011).